Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.

Schniepp R, Jakl V, Wuehr M, Havla J, Kümpfel T, Dieterich M, Strupp M, Jahn K.

Mult Scler. 2013 Apr;19(4):506-8. doi: 10.1177/1352458512461394. Epub 2012 Oct 15.

PMID:
23069878
2.

Fampridine improves severe dysarthria in secondary-progressive multiple sclerosis.

Schmidt S.

Mult Scler. 2013 Apr;19(4):511. doi: 10.1177/1352458512458554. Epub 2012 Aug 30. No abstract available.

PMID:
22936332
3.

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.

Dunn J, Blight A.

Curr Med Res Opin. 2011 Jul;27(7):1415-23. doi: 10.1185/03007995.2011.583229. Epub 2011 May 20. Review.

PMID:
21595605
4.

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.

Blight AR, Henney HR 3rd, Cohen R.

Ann N Y Acad Sci. 2014 Nov;1329:33-44. doi: 10.1111/nyas.12512. Epub 2014 Aug 25. Review.

5.

Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report.

Löhle M, Schrempf W, Wolz M, Reichmann H, Storch A.

Mov Disord. 2008 Jul 15;23(9):1314-6. doi: 10.1002/mds.22071.

PMID:
18442126
6.

Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.

Lugaresi A.

Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):295-306. doi: 10.1517/17425255.2015.993315. Epub 2014 Dec 16. Review.

PMID:
25510833
7.

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.

Cornblath DR, Bienen EJ, Blight AR.

Clin Ther. 2012 May;34(5):1056-69. doi: 10.1016/j.clinthera.2012.03.007. Epub 2012 Apr 11. Review.

PMID:
22497693
8.

Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.

Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T.

Neurology. 2004 May 11;62(9):1623-5.

PMID:
15136697
9.

Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.

Rabadi MH, Kreymborg K, Vincent AS.

Drugs R D. 2013 Sep;13(3):175-81. doi: 10.1007/s40268-013-0020-x.

10.

Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.

Cameron MH, Fitzpatrick M, Overs S, Murchison C, Manning J, Whitham R.

Mult Scler. 2014 May;20(6):733-8. doi: 10.1177/1352458513507356. Epub 2013 Oct 7.

PMID:
24099749
11.

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR 3rd, Blight AR; MS-F203, MS-F204, and Extension Study Investigators.

Mult Scler. 2015 Sep;21(10):1322-31. doi: 10.1177/1352458514563591. Epub 2015 Jan 12.

12.

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators.

Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240.

PMID:
20976768
13.

Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.

Fernandez O, Berger T, Hartung HP, Putzki N.

Expert Rev Clin Pharmacol. 2012 Nov;5(6):649-65. doi: 10.1586/ecp.12.59. Epub 2012 Nov 13.

PMID:
23146002
14.

Dalfampridine: a medication to improve walking in patients with multiple sclerosis.

Pikoulas TE, Fuller MA.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1010-5. doi: 10.1345/aph.1Q714. Epub 2012 Jul 3. Review.

PMID:
22764324
15.

Assessing dalfampridine efficacy in the physician's office.

Raffel JB, Malik O, Nicholas RS.

Mult Scler. 2014 Jan;20(1):24-6. doi: 10.1177/1352458513489601. Epub 2013 May 31.

PMID:
23727943
16.

Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.

Egeberg MD, Oh CY, Bainbridge JL.

Clin Ther. 2012 Nov;34(11):2185-94. doi: 10.1016/j.clinthera.2012.10.003. Epub 2012 Nov 2. Review. Erratum in: Clin Ther. 2013 Jun;35(6):900.

PMID:
23123001
17.

Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy).

Goodman AD, Stone RT.

Neurotherapeutics. 2013 Jan;10(1):106-10. doi: 10.1007/s13311-012-0156-3. Review.

18.

Long-term effects of dalfampridine in patients with multiple sclerosis.

Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, Meuth SG.

J Neurol Sci. 2014 Feb 15;337(1-2):18-24. doi: 10.1016/j.jns.2013.11.011. Epub 2013 Nov 16.

PMID:
24290498
19.

Dalfampridine approved for MS.

Traynor K.

Am J Health Syst Pharm. 2010 Mar 1;67(5):335. doi: 10.2146/news100015. No abstract available. Erratum in: Am J Health Syst Pharm. 2010 Apr 15;67(8):594. Dosage error in article text.

PMID:
20172978
20.

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

Preiningerova JL, Baumhackl U, Csepany T, Czaplinski A, Deisenhammer F, Derfuss T, Fabjan TH, Fazekas F, Fuchs S, Havrdova E, Ledinek AH, Illes Z, Jazbec SS, Klimova E, Komoly S, Kurca E, Linnebank M, Lisy L, Mares J, Prochazkova L, Csilla R, Szilasiova J, Stourac P, Talab R, Turcani P, Vachova M, Vecsei L, Vodusek D, Zapletalova O, Berger T.

CNS Neurosci Ther. 2013 May;19(5):302-6. doi: 10.1111/cns.12101.

PMID:
23607697

Supplemental Content

Support Center